Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology
April 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics
Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …
KaloBios announces new affordable pricing model, refuses to engage in “price gouging”
April 12, 2016Manufacturing and Production, Sales and Marketing CEO, Drug pricing, KaloBios, Martin Shkreli, Shkreli, affordable, price gouging, price model, responsible
Price gouging has become synonymous with drug costs in the US, with the infamous Martin Shkreli and troubled Valeant becoming …
Clinical studies point to consistent efficacy in AstraZeneca’s treatment for drug-resistance bacteria
April 12, 2016Manufacturing and Production, Research and Development AstraZeneca, avibactam, ceftazidime, gram resistant
AstraZeneca has presented results from a series of trials which show the consistent efficacy of investigational antibiotic, ceftazidime-avibactam (CAZ-AVI) in …
Roche’s Venclexta gets accelerated approval from US FDA for chronic lymphocytic leukemia
April 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Roche, US FDA, Venclexta, chronic lymphocytic leukemia
Swiss drug firm Roche (SIX: ROG) on Tuesday said the US Food and Drug Administration (FDA) has granted accelerated approval …
Insys Therapeutics sees revenue from Subsys at $61-$62 million; shares plunge 21%
April 11, 2016Business Services, Manufacturing and Production, Sales and Marketing Insys Therapeutics, Stock Price, Subsys, opioids, pain drug
Insys Therapeutics Inc (Nasdaq: INSY) stock plunged nearly 21% Monday after the company said sales for its pain drug will …
IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition
April 11, 2016Medical Communications, Research and Development Bristol-Myers Squibb, Gilead, HIV, anti-HIV
German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally …
GW Pharma starts Phase III trials for Tuberous Sclerosis Complex drug
April 11, 2016Research and Development Epidiolex, GW Pharmaceuticals, Tuberous Sclerosis Complex, genetics, rare disease
GW Pharmaceuticals Plc (Nasdaq: GWPH) said it has started late-stage trials for its Epidiolex (cannabidiol or CBD) to treat seizures …
Mylan launches new dosages of generic of Novartis hypertension drug in US
April 11, 2016Manufacturing and Production Mylan, Novartis, generic, high blood pressure, hypertension
Mylan (TASE: MYL) has announced the US launch of new dosages of its generic version of Novartis’s hypertension drug, Lopressor …
Former US CEO of Boehringer Ingelheim becomes chairman at Inotek Pharmaceuticals
April 11, 2016Medical Communications Boehringer Ingelheim, inotek, inotek pharma, j martin carroll
Inotek Pharmaceuticals has announced the appointment of J. Martin Carroll as the new chairman of the board. Carroll will succeed …
Weekly Movers: Array BioPharma, Amicus Therapeutics, Genocea Biosciences, Tesaro Inc, Incyte, Clovis Oncology
April 11, 2016Manufacturing and Production, Research and Development, Sales and Marketing Index, Movers, markets, stocks
Shares in Botox-maker Allergan (NYSE: AGN) plunged over 17% in intra-day trading as the $160 billion merger seal with US …
Depomed criticised by investors and urged to explore potential sale
April 11, 2016Sales and Marketing Depomed, board, horizon, sale, starboard, starboard value
Only a few short months after fighting off a $1 billion bid from Horizon Pharma, investors at Depomed have called …
FDA staff raises doubts on efficacy, safety of Clovis’ trial drug for lung cancer, shares plunge
April 11, 2016AstraZeneca, Clovis Oncology, US FDA, drug trial, lung cancer, regulation, rociletinib
Shares in Clovis Oncology Inc (Nasdaq: CLVS) plunged to close down nearly 18% after the US regulators expressed doubts if …
Roche’s cancer immunotherapy for lung cancer gets US FDA priority review
April 11, 2016Business Services, Research and Development, Sales and Marketing Roche, US FDA, atezolizumab, lung cancer
Swiss drug firm Roche (SIX: ROG) on Monday said the US Food and Drug Administration (FDA) has accepted its Biologics …
Midatech launch treatment to reduce chemo-induced vomiting in the US
April 11, 2016Research and Development, Sales and Marketing chemotherapy, midatech, nausea, oncology, radiation, vomiting
Midatech Pharma (NASDAQ: MTP) has the full commercial launch of Zuplenz (ondansetron) in the US. The drug is an oral …
Sun Pharma receives FDA approval for ocular pain treatment
April 11, 2016Research and Development, Sales and Marketing FDA, Sun Pharma, bromsite, ocular treatment
Sun Pharma (BSE: 524715) has announced that their ocular pain prevention treatment, BromSite (bromfenac ophthalmic solution), has been approved by …
Celgene says disappointed with NICE decision to not back blood cancer drug
April 8, 2016Business Services, Medical Communications, Sales and Marketing
US drugmaker Celgene Corp (Nasdaq: CELG) on Friday said it is disappointed with UK regulators’ decision to not recommend Vidaza …
HIV successfully overcomes CRISPR gene-editing technology
April 8, 2016Research and Development HIV, crispr, failure, setback
Researchers using the CRISPR gene-editing technology have indicated that HIV can defeat efforts to cripple it, but have characterised it …
US panel supports accelerated approval for Intercept’s trial drug for rare liver condition
April 8, 2016Medical Communications, Research and Development, Sales and Marketing Intercept Pharmaceuticals, PDUFA, US FDA, liver disorder, rare disease
Intercept Pharmaceuticals (Nasdaq: ICPT) said a US Food and Drug Administration (FDA) advisory committee has recommended accelerated approval for its …
UK’s genomics and personalised medicine expertise showcased at major international gathering
April 8, 2016Manufacturing and Production, Research and Development 000 genomics project, 100, NHS, UK, expertise, genomics, international gathering, world leader
The UK’s expertise in genomics was showcased at a major international gathering to foster global collaboration in this burgeoning field. …
Pfizer, IBM partner to develop monitoring system for Parkinson’s disease
April 8, 2016Medical Communications, Research and Development Parkinson's disease, Pfizer, collaboration, ibm, research, technology
US pharma giant Pfizer (NYSE: PFE) and International Business Machines Corp (NYSE: IBM) have partnered on a research project focussed on …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
